GoldenSite™-enabled next generation protein-drug-conjugates
Not Disclosed (Oncology focus)
PreclinicalActive
Key Facts
About VALANX Biotech
VALANX Biotech is a private, preclinical-stage biotech developing a novel protein conjugation platform called GoldenSite™. The technology enables site-specific, fast, and catalyst-free conjugation at virtually any site on a protein, aiming to produce homogeneous conjugates with superior biophysical properties akin to unconjugated antibodies. This approach seeks to enhance the therapeutic window of ADCs by allowing higher dosing with reduced toxicity, thereby addressing key limitations of current ADC technologies. The company is building its internal pipeline while positioning its platform for potential partnerships.
View full company profile